Progesterone protects normative anxiety-like responding among ovariectomized female mice that conditionally express the HIV-1 regulatory protein, Tat, in the CNS

Hormones and Behavior

Volumn 65, Issue 5, 2014, Pages 445-453

  Paris, Jason J ^a   Fenwick, Jason ^a   McLaughlin, Jay P ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

17 estradiol; Elevated plus maze; Estrous cycle; GT tg bigenic mice; Marble burying; Neuroaids; Open field; Ovariectomy; Transactivating transcriptor

Indexed keywords

DOXYCYCLINE; ESTRADIOL; PROGESTERONE; SODIUM CHLORIDE; TRANSACTIVATOR PROTEIN; ESTROGEN; GESTAGEN;

ANIMAL BEHAVIOR; ANXIETY DISORDER; ARTICLE; DRUG EFFECT; DRUG MECHANISM; ELEVATED PLUS MAZE TEST; EXPERIMENTAL ANXIETY TEST; FEMALE; IN VITRO STUDY; MARBLE BURYING TASK; MENTAL TASK; MOUSE; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TASK PERFORMANCE; ANIMAL; ANXIETY; BIOSYNTHESIS; BRAIN LEVEL; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS; ESTRUS CYCLE; GENETICS; MALE; METABOLISM; OVARIECTOMY; PSYCHOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM; DOXYCYCLINE; ESTRADIOL; ESTROGENS; ESTROUS CYCLE; FEMALE; MALE; MICE; MICE, TRANSGENIC; OVARIECTOMY; PROGESTERONE; PROGESTINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84899655556     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2014.04.001     Document Type: Article

References (101)

1. Adams S.M., Aksenova M.V., Aksenov M.Y., Mactutus C.F., Booze R.M. ER-β mediates 17β-estradiol attenuation of HIV-1 Tat-induced apoptotic signaling. Synapse 2010, 64:829-838.
2. Adams S.M., Aksenova M.V., Aksenov M.Y., Mactutus C.F., Booze R.M. Soy isoflavones genistein and daidzein exert anti-apoptotic actions via a selective ER-mediated mechanism in neurons following HIV-1 Tat(1-86) exposure. PLoS One 2012, 7:e37540.
3. Baeten J.M., Lavreys L., Sagar M., Kreiss J.K., Richardson B.A., Chohan B., Panteleeff D., Mandaliya K., Ndinya-Achola J.O., Overbaugh J., Farley T., Mwachari C., Cohen C., Chipato T., Jaisamrarn U., Kiriwat O., Duerr A. Effect of contraceptive methods on natural history of HIV: studies from the Mombasa cohort. J. Acquir. Immune Defic. Syndr. 2005, 38:S18-S21.
4. Bali A., Jaggi A.S. Multifunctional aspects of allopregnanolone in stress and related disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 48C:64-78.
5. Bing E.G., Burnam M.A., Longshore D., Fleishman J.A., Sherbourne C.D., London A.S., Turner B.J., Eggan F., Beckman R., Vitiello B., Morton S.C., Orlando M., Bozzette S.A., Ortiz-Barron L., Shapiro M. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch. Gen. Psychiatry 2001, 58:721-728.
6. Boissé L., Gill M.J., Power C. HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol. Clin. 2008, 26:799-819.
7. Boonyanurak P., Bunupuradah T., Wilawan K., Lueanyod A., Thongpaeng P., Chatvong D., Sophonphan J., Saeloo S., Ananworanich J., Chaithongwongwatthana S. Age at menopause and menopause-related symptoms in human immunodeficiency virus-infected Thai women. Menopause 2012, 19:820-824.
8. Broekkamp C.L., Rijk H.W., Joly Gelouin D., Lloyd K.L. Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim induced grooming in mice. Eur. J. Pharmacol. 1986, 126:223-229.
9. Bronson F.H., Vom Saal F.S. Control of the preovulatory release of luteinizing hormone by steroids in the mouse. Endocrinology 1979, 104:1247-1255.
10. Cabrera-Muñoz E., Hernández-Hernández O.T., Camacho-Arroyo I. Role of estradiol and progesterone in HIV susceptibility and disease progression. Mini-Rev. Med. Chem. 2012, 12:1049-1054.
11. Cabrera-Muñoz E., Fuentes-Romero L.L., Zamora-Chávez J., Camacho-Arroyo I., Soto-Ramírez L.E. Effects of progesterone on the content of CCR5 and CXCR4 coreceptors in PBMCs of seropositive and exposed but uninfected Mexican women to HIV-1. J. Steroid Biochem. Mol. Biol. 2012, 132:66-72.
12. Carey A.N., Sypek E.I., Singh H.D., Kaufman M.J., McLaughlin J.P. Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse. Behav. Brain Res. 2012, 229:48-56.
13. Carey A.N., Liu X., Mintzopoulos D., Paris J.J., Muschamp J.W., McLaughlin J.P., Kaufman M.J. Conditional Tat protein expression in the GT-tg bigenic mouse brain induces gray matter density reductions. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 43:49-54.
14. Chen M.F., Soldan S., Kolson D.L. HIV neuroinvasion: early events, late manifestations. Chemokine Receptors and NeuroAIDS: Beyond Co-Receptor Function and Links to Other Neuropathologies 2010, 5-32. Springer, New York. O. Meucci (Ed.).
15. Clemetson D.B., Moss G.B., Willerford D.M., Hensel M., Emonyi W., Holmes K.K., Plummer F., Ndinya-Achola J., Roberts P.L., Hillier S., Kreiss J.K. Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA 1993, 269:2860-2864.
16. Cohen M.S., Chen Y.Q., McCauley M., Gamble T., Hosseinipour M.C., Kumarasamy N., Hakim J.G., Kumwenda J., Grinsztejn B., Pilotto J.H., Godbole S.V., Mehendale S., Chariyalertsak S., Santos B.R., Mayer K.H., Hoffman I.F., Eshleman S.H., Piwowar-Manning E., Wang L., Makhema J., Mills L.A., de Bruyn G., Sanne I., Eron J., Gallant J., Havlir D., Swindells S., Ribaudo H., Elharrar V., Burns D., Taha T.E., Nielsen-Saines K., Celentano D., Essex M., Fleming T.R. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 2011, 365:493-505. HPTN 052 Study Team.
17. Crawley J.N., Paylor R. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm. Behav. 1997, 31:197-211.
18. El-Hage N., Gurwell J.A., Singh I.N., Knapp P.E., Nath A., Hauser K.F. Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia 2005, 50:91-106.
19. Evans D.L., Mason K., Bauer R., Leserman J., Pettito J. Neuropsychiatric manifestations of HIV-1 infection and AIDS. Neuropsychopharmacology: The Fifth Generation of Progress 2002, 1281-1399. Raven Press, New York. D. Charney, J. Coyle, K. Davis, C. Nemeroff (Eds.).
20. Evans D.L., Charney D.S., Lewis L., Golden R.N., Gorman J.M., Krishnan K.R., Nemeroff C.B., Bremner J.D., Carney R.M., Coyne J.C., Delong M.R., Frasure-Smith N., Glassman A.H., Gold P.W., Grant I., Gwyther L., Ironson G., Johnson R.L., Kanner A.M., Katon W.J., Kaufmann P.G., Keefe F.J., Ketter T., Laughren T.P., Leserman J., Lyketsos C.G., McDonald W.M., McEwen B.S., Miller A.H., Musselman D., O'Connor C., Petitto J.M., Pollock B.G., Robinson R.G., Roose S.P., Rowland J., Sheline Y., Sheps D.S., Simon G., Spiegel D., Stunkard A., Sunderland T., Tibbits P., Valvo W.J. Mood disorders in the medically ill: scientific review and recommendations. Biol. Psychiatry 2005, 58:175-189.
21. Fan M.D., Maslow B.S., Santoro N., Schoenbaum E. HIV and the menopause. Menopause Int. 2008, 14:163-168.
22. Frye C.A., Paris J.J. Effects of neurosteroid actions at N-methyl-d-aspartate and GABA A receptors in the midbrain ventral tegmental area for anxiety-like and mating behavior of female rats. Psychopharmacology (Berl) 2011, 213:93-103.
23. Frye C.A., Rhodes M.E. Progestin concentrations are increased following paced mating in midbrain, hippocampus, diencephalon, and cortex of rats in behavioral estrus, but only in midbrain of diestrous rats. Neuroendocrinology 2006, 83:336-347.
24. Frye C.A., Paris J.J., Rhodes M.E. Estrogen is necessary for 5α-pregnan-3α-ol-20-one (3α,5α-THP) infusion to the ventral tegmental area to facilitate social and sexual, but neither exploratory nor affective behavior of ovariectomized rats. Pharmacol. Biochem. Behav. 2008, 91:261-270.
25. Goggin K., Engelson E.S., Rabkin J.G., Kotler D.P. The relationship of mood, endocrine, and sexual disorders in human immunodeficiency virus positive (HIV+) women: an exploratory study. Psychosom. Med. 1998, 60:11-16.
26. Hall C., Ballachey E.L. A study of the rat's behavior in a field: a contribution to method in comparative psychology. Univ. Calif. Publ. Psychol. 1932, 6:1-12.
27. Härkönen P.L., Väänänen H.K. Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators. Ann. N. Y. Acad. Sci. 2006, 1089:218-227.
28. Haughey N.J., Holden C.P., Nath A., Geiger J.D. Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein tat. J. Neurochem. 1999, 73:1363-1374.
29. Imai K., Sutton M.Y., Mdodo R., Del Rio C. HIV and menopause: a systematic review of the effects of HIV infection on age at menopause and the effects of menopause on response to antiretroviral therapy. Obstet. Gynecol. Int. 2013, 2013:340309.
30. Jeang K.T., Chang Y., Berkhout B., Hammarskjöld M.L., Rekosh D. Regulation of HIV expression: mechanisms of action of Tat and Rev. AIDS 1991, 5:S3-S14.
31. 3H]ifenprodil to the N-methyl-d-aspartate receptor in rat frontal cortex membrane. J. Steroid Biochem. Mol. Biol. 2005, 94:263-266.
32. Kagee A., Martin L. Symptoms of depression and anxiety among a sample of South African patients living with HIV. AIDS Care 2010, 22:159-165.
33. Kanapathipillai R., Hickey M., Giles M. Human immunodeficiency virus and menopause. Menopause 2013, 20:983-990.
34. Karim R., Mack W.J., Kono N., Tien P.C., Anastos K., Lazar J., Young M., Cohen M., Golub E., Greenblatt R.M., Kaplan R.C., Hodis H.N. Gonadotropin and sex steroid levels in HIV-infected premenopausal women and their association with subclinical atherosclerosis in HIV-infected and -uninfected women in the women's interagency HIV study (WIHS). J. Clin. Endocrinol. Metab. 2013, 98:E610-E618.
35. Kendall S.L., Anderson C.F., Nath A., Turchan-Cholewo J., Land C.L., Mactutus C.F., Booze R.M. Gonadal steroids differentially modulate neurotoxicity of HIV and cocaine: testosterone and ICI 182,780 sensitive mechanism. BMC Neurosci. 2005, 6:40.
36. Kessler R.C., McGonagle K.A., Swartz M., Blazer D.G., Nelson C.B. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J. Affect. Disord. 1993, 29:85-96.
37. Kim B.O., Liu Y., Ruan Y., Xu Z.C., Schantz L., He J.J. Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am. J. Pathol. 2003, 162:1693-1707.
38. Kim H.J., Martemyanov K.A., Thayer S.A. Human immunodeficiency virus protein Tat induces synapse loss via a reversible process that is distinct from cell death. J. Neurosci. 2008, 28:12604-12613.
39. Koonce C.J., Walf A.A., Frye C.A. Type 1 5α-reductase may be required for estrous cycle changes in affective behaviors of female mice. Behav. Brain Res. 2012, 226:376-380.
40. Kraft-Terry S.D., Stothert A.R., Buch S., Gendelman H.E. HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol. Dis. 2010, 37:542-548.
41. Kruman I.I., Nath A., Mattson M.P. HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Exp. Neurol. 1998, 154:276-288.
42. Lad H.V., Liu L., Paya-Cano J.L., Parsons M.J., Kember R., Fernandes C., Schalkwyk L.C. Behavioural battery testing: evaluation and behavioural outcomes in 8 inbred mouse strains. Physiol. Behav. 2010, 99:301-316.
43. Lawson M.A., Kelley K.W., Dantzer R. Intracerebroventricular administration of HIV-1 Tat induces brain cytokine and indoleamine 2,3-dioxygenase expression: a possible mechanism for AIDS comorbid depression. Brain Behav. Immun. 2011, 25:1569-1575.
44. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 1987, 92:180-185.
45. Lopes M., Olfson M., Rabkin J., Hasin D.S., Alegría A.A., Lin K.H., Grant B.F., Blanco C. Gender, HIV status, and psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry 2012, 73:384-391.
46. Magnuson D.S., Knudsen B.E., Geiger J.D., Brownstone R.M., Nath A. Human immunodeficiency virus type 1 tat activates non-N-methyl-d-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann. Neurol. 1995, 37:373-380.
47. Malayev A., Gibbs T.T., Farb D.H. Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids. Br. J. Pharmacol. 2002, 135:901-909.
48. Maragos W.F., Young K.L., Turchan J.T., Guseva M., Pauly J.R., Nath A., Cass W.A. Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J. Neurochem. 2002, 83:955-963.
49. Massie M.J. Prevalence of depression in patients with cancer. J. Natl. Cancer Inst. Monogr. 2004, 32:57-71.
50. Maurice T., Grégoire C., Espallergues J. Neuro(active)steroids actions at the neuromodulatory sigma1 (sigma1) receptor: biochemical and physiological evidences, consequences in neuroprotection. Pharmacol. Biochem. Behav. 2006, 84:581-597.
51. McArthur J.C. HIV dementia: an evolving disease. J. Neuroimmunol. 2004, 157:3-10.
52. McArthur J.C., Haughey N., Gartner S., Conant K., Pardo C., Nath A., Sacktor N. Human immunodeficiency virus-associated dementia: an evolving disease. J. Neurovirol. 2003, 9:205-221.
53. McIlwain K.L., Merriweather M.Y., Yuva-Paylor L.A., Paylor R. The use of behavioral test batteries: effects of training history. Physiol. Behav. 2001, 73:705-717.
54. Melcangi R.C., Poletti A., Cavarretta I., Celotti F., Colciago A., Magnaghi V., Motta M., Negri-Cesi P., Martini L. The 5α-reductase in the central nervous system: expression and modes of control. J. Steroid Biochem. Mol. Biol. 1998, 65:295-299.
55. Micevych P., Sinchak K. The neurosteroid progesterone underlies estrogen positive feedback of the LH surge. Front. Endocrinol. (Lausanne) 2011, 2:90.
56. Michael S.D. Plasma prolactin and progesterone during the estrous cycle in the mouse. Proc. Soc. Exp. Biol. Med. 1976, 153:254-257.
57. Mollace V., Nottet H.S., Clayette P., Turco M.C., Muscoli C., Salvemini D., Perno C.F. Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends Neurosci. 2001, 24:411-416.
58. 3H]norepinephrine release evoked by N-methyl-d-aspartate in the rat hippocampus. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:3774-3778.
59. Morgan M.A., Pfaff D.W. Effects of estrogen on activity and fear-related behaviors in mice. Horm. Behav. 2001, 40:472-482.
60. Morgan M.A., Pfaff D.W. Estrogen's effects on activity, anxiety, and fear in two mouse strains. Behav. Brain Res. 2002, 132:85-93.
61. Mostad S.B., Overbaugh J., DeVange D.M., Welch M.J., Chohan B., Mandaliya K., Nyange P., Martin H.L., Ndinya-Achola J., Bwayo J.J., Kreiss J.K. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 1997, 350:922-927.
62. Nath A., Psooy K., Martin C., Knudsen B., Magnuson D.S., Haughey N., Geiger J.D. Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J. Virol. 1996, 70:1475-1480.
63. New D.R., Maggirwar S.B., Epstein L.G., Dewhurst S., Gelbard H.A. HIV-1 Tat induces neuronal death via tumor necrosis factor-alpha and activation of non-N-methyl-d-aspartate receptors by a NFkappaB-independent mechanism. J. Biol. Chem. 1998, 273:17852-17858.
64. Orlando M., Burnam M.A., Beckman R., Morton S.C., London A.S., Bing E.G., Fleishman J.A. Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: results from the HIV Cost and Services Utilization Study. Int. J. Methods Psychiatr. Res. 2002, 11:75-82.
65. Parada C.A., Roeder R.G. A novel RNA polymerase II-containing complex potentiates Tat-enhanced HIV-1 transcription. EMBO J. 1999, 18:3688-3701.
66. Paris J.J., Walf A.A., Frye C.A. II. Cognitive performance of middle-aged female rats is influenced by capacity to metabolize progesterone in the prefrontal cortex and hippocampus. Brain Res. 2011, 1379:149-163.
67. Paris J.J., Carey A.N., Shay C.F., Gomes S.M., He J.J., McLaughlin J.P. Effects of Conditional Central Expression of HIV-1 Tat Protein to Potentiate Cocaine-Mediated Psychostimulation and Reward Among Male Mice. Neuropsychopharmacology 2014, 39:380-388.
68. Paris J.J., Singh H.D., Ganno M.L., Jackson P., McLaughlin J.P. Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat. Psychopharmacology (Berl) 2014, (in press). 10.1007/s00213-013-3385-1.
69. Pence B.W., Miller W.C., Gaynes B.N., Eron J.J. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2007, 44:159-166.
70. Perumal M.B., Dhanasekaran S. HIV associated dementia: role for neurosteroids. Med. Hypotheses 2012, 78:672-674.
71. Poling A., Cleary J., Monaghan M. Burying by rats in response to aversive and nonaversive stimuli. J. Exp. Anal. Behav. 1981, 35:31-44.
72. Prior J.C., Hitchcock C.L. The endocrinology of perimenopause: need for a paradigm shift. Front. Biosci. (Schol. Ed.) 2011, 3:474-486.
73. Ragupathy V., Devadas K., Tang S., Wood O., Lee S., Dastyer A., Wang X., Dayton A., Hewlett I. Effect of sex steroid hormones on replication and transmission of major HIV subtypes. J. Steroid Biochem. Mol. Biol. 2013, 138C:63-71.
74. Rodriguez-Garcia M., Biswas N., Patel M.V., Barr F.D., Crist S.G., Ochsenbauer C., Fahey J.V., Wira C.R. Estradiol reduces susceptibility of CD4+ T cells and macrophages to HIV-infection. PLoS One 2013, 8:e62069.
75. Royal W., Zhang L., Guo M., Jones O., Davis H., Bryant J.L. Immune activation, viral gene product expression and neurotoxicity in the HIV-1 transgenic rat. J. Neuroimmunol. 2012, 247:16-24.
76. Sacktor N., McDermott M.P., Marder K., Schifitto G., Selnes O.A., McArthur J.C., Stern Y., Albert S., Palumbo D., Kieburtz K., De Marcaida J.A., Cohen B., Epstein L. HIV-associated cognitive impairment before and after the advent of combination therapy. J. Neurovirol. 2002, 8:136-142.
77. Sayeed I., Stein D.G. Progesterone as a neuroprotective factor in traumatic and ischemic brain injury. Prog. Brain Res. 2009, 175:219-237.
78. Sayeed I., Guo Q., Hoffman S.W., Stein D.G. Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion. Ann. Emerg. Med. 2006, 47:381-389.
79. Scharfman H.E., MacLusky N.J. The influence of gonadal hormones on neuronal excitability, seizures, and epilepsy in the female. Epilepsia 2006, 47:1423-1440.
80. Scharko A.M. DSM psychiatric disorders in the context of pediatric HIV/AIDS. AIDS Care 2006, 18:441-445.
81. Schumacher M., Mattern C., Ghoumari A., Oudinet J.P., Liere P., Labombarda F., Sitruk-Ware R., De Nicola A.F., Guennoun R. Revisiting the roles of progesterone and allopregnanolone in the nervous system: Resurgence of the progesterone receptors. Prog. Neurobiol. 2014, 113:6-39.
82. Smith S.S. Progesterone administration attenuates excitatory amino acid responses of cerebellar Purkinje cells. Neuroscience 1991, 42:309-320.
83. Soares C.N. Mood disorders in midlife women: understanding the critical window and its clinical implications. Menopause 2014, 21:198-206.
84. Sordo del Castillo L., Ruiz-Pérez I., Olry de Labry Lima A. Biological, psychosocial, therapeutic and quality of life inequalities between HIV-positive men and women - a review from a gender perspective. AIDS Rev. 2010, 12:113-120.
85. Starling I., Wright A., Arbuthnott G., Harkiss G. Acute in vivo neurotoxicity of peptides from Maedi Visna virus transactivating protein Tat. Brain Res. 1999, 830:285-291.
86. Stein D.G. A clinical/translational perspective: can a developmental hormone play a role in the treatment of traumatic brain injury?. Horm. Behav. 2013, 63:291-300.
87. Stringer E.M., Kaseba C., Levy J., Sinkala M., Goldenberg R.L., Chi B.H., Matongo I., Vermund S.H., Mwanahamuntu M., Stringer J.S. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am. J. Obstet. Gynecol. 2007, 197:e1-e8. (144).
88. Stringer E.M., Levy J., Sinkala M., Chi B.H., Matongo I., Chintu N., Stringer J.S. HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial. AIDS 2009, 23:1377-1382.
89. Su L., Sun Y., Ma F., Lü P., Huang H., Zhou J. Progesterone inhibits Toll-like receptor 4-mediated innate immune response in macrophages by suppressing NF-kappaB activation and enhancing SOCS1 expression. Immunol. Lett. 2009, 125:151-155.
90. Turchan J., Anderson C., Hauser K.F., Sun Q., Zhang J., Liu Y., Wise P.M., Kruman I., Maragos W., Mattson M.P., Booze R., Nath A. Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine. BMC Neurosci. 2001, 2:3.
91. Vassiliadou N., Tucker L., Anderson D.J. Progesterone-induced inhibition of chemokine receptor expression on peripheral blood mononuclear cells correlates with reduced HIV-1 infectability in vitro. J. Immunol. 1999, 162:7510-7518.
92. Vergote D., Butler G.S., Ooms M., Cox J.H., Silva C., Hollenberg M.D., Jhamandas J.H., Overall C.M., Power C. Proteolytic processing of SDF-1alpha reveals a change in receptor specificity mediating HIV-associated neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:19182-19187.
93. Walf A.A., Rhodes M.E., Frye C.A. Ovarian steroids enhance object recognition in naturally cycling and ovariectomized, hormone-primed rats. Neurobiol. Learn. Mem. 2006, 86:35-46.
94. Walf A.A., Paris J.J., Frye C.A. Chronic estradiol replacement to aged female rats reduces anxiety-like and depression-like behavior and enhances cognitive performance. Psychoneuroendocrinology 2009, 34:909-916.
95. Wallace D.R., Dodson S., Nath A., Booze R.M. Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 2006, 59:51-60.
96. Wang C.C., McClelland R.S., Overbaugh J., Reilly M., Panteleeff D.D., Mandaliya K., Chohan B., Lavreys L., Ndinya-Achola J., Kreiss J.K. The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS 2004, 18:205-209.
97. Wood P.A., Bove K., You S., Chambers A., Hrushesky W.J. Cancer growth and spread are saltatory and phase-locked to the reproductive cycle through mediators of angiogenesis. Mol. Cancer Ther. 2005, 4:1065-1075.
98. Yadav A., Collman R.G. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J. Neuroimmune Pharmacol. 2009, 4:430-447.
99. 3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes. J. Pharmacol. Exp. Ther. 2009, 329:1071-1083.
100. Zhu X., Yao H., Peng F., Callen S., Buch S. PDGF-mediated protection of SH-SY5Y cells against Tat toxin involves regulation of extracellular glutamate and intracellular calcium. Toxicol. Appl. Pharmacol. 2009, 240:286-291.
101. Zhu J., Ananthan S., Mactutus C.F., Booze R.M. Recombinant human immunodeficiency virus-1 transactivator of transcription1-86 allosterically modulates dopamine transporter activity. Synapse 2011, 65:1251-1254.